A direct-to-consumer test designed to provide information about genetic variants that may be linked with a patient's ability to metabolize some medications has been given the green light from the FDA. The 23andme Personal Genome Service Pharmacogenetic Reports test has been authorized to detect 33 variants for multiple genes.